This funding will support AlzeCure’s planned Phase IIa study of NeuroRestore ACD856 in Alzheimer’s patients, it states. In addition, higher doses of ACD856 will be evaluated in humans, as the good safety profile allows for further dosing.

ACD856 has the potential to be the first drug in a new category of Alzheimer’s drugs – positive allosteric modulators of Trk receptors (Trk-PAMs), which increase BDNF and NGF signaling, describes the company.

”The support from the EIC Accelerator program is a recognition of the project and will be crucial in advancing our clinical trials and bringing this much-needed Alzheimer’s treatment to patients,” says Johan Sandin, Chief Scientific Officer at AlzeCure Pharma.

ACD856

ACD856 is a first-in-class drug candidate for Alzheimer’s disease with possible positive effects on both memory function and the course of the disease. Phase I clinical studies have shown good safety and tolerability with the substance and that it enters the brain to a high extent and activates regions of the brain with relevance for both cognition and depression. Previous preclinical studies have also shown that AlzeCure’s drug candidate ACD856 in the NeuroRestore platform strengthens communication between nerve cells and improves cognitive ability, including learning and memory functions. Furthermore, preclinical results also show neuroprotective, anti-inflammatory and disease-modifying effects in various models with these so-called Trk-PAM substances, which increase BDNF and NGF signaling in the brain.

“The grant we received from the European Innovation Council is a strong validation of NeuroRestore ACD856, which has a unique pharmacological mechanism that enables multiple indications, both neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease, but also, for example, depression,” says Martin Jönsson, CEO of AlzeCure Pharma. ”That ACD856 has the potential to both improve learning and memory capacity, as well as being disease-modifying and improving brain health is unique and significant”.